{"id":409059,"date":"2019-08-30T00:00:00","date_gmt":"2019-08-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0002-2019-biopharma-biosimilars-current-treatment-endocrinology-us-eu-2019\/"},"modified":"2026-03-31T10:46:23","modified_gmt":"2026-03-31T10:46:23","slug":"biosbi0002-2019-biopharma-biosimilars-current-treatment-endocrinology-us-eu-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0002-2019-biopharma-biosimilars-current-treatment-endocrinology-us-eu-2019\/","title":{"rendered":"Biosimilars | Current Treatment | Endocrinology | US\/EU | 2019"},"content":{"rendered":"<p>The biosimilar\/noninnovator sector of the endocrinology market is evolving. Eli Lilly\/Boehringer Ingelheim\u2019s Abasaglar\/Basaglar was the first biosimilar\/noninnovator insulin glargine to launch in Europe and the United States. Subsequently, the EC has approved Biocon\/Mylan\u2019s insulin glargine biosimilar, Semglee, and more recently, Sanofi has launched Admelog, the first insulin lispro biosimilar to be available in the United States, also available in Europe under the brand name Insulin lispro\u00a0Sanofi.<\/p>\n<p>The prescribing behavior of endocrinologists will directly impact the uptake of these products, including insulin brands such as Sanofi\u2019s Lantus and Eli Lilly\u2019s Humalog. Understanding physicians\u2019 attitude and behavior toward biosimilars is critical for development and marketing strategies aimed at persuading endocrinologists to prescribe and drive biosimilar\/noninnovator uptake.<\/p>\n<p>DRG\u2019s primary research with endocrinologists in the United States, France, and Germany allows us to assess the dynamics determining current and future biosimilar\/noninnovator uptake within the endocrinology space.<\/p>\n<p>This report\u00a0includes the following topics:<\/p>\n<ul>\n<li>Physicians\u2019 current experience and familiarity with biosimilars.<\/li>\n<li>Current levels of biosimilar prescribing.<\/li>\n<li>Main drivers and barriers influencing biosimilar uptake.<\/li>\n<li>Impact of cost and clinical data on biosimilar uptake.<\/li>\n<\/ul>\n<p><strong>Scope <\/strong><\/p>\n<p><strong>Markets covered:<\/strong> United States, France, and Germany.<\/p>\n<p><strong>Primary research: <\/strong>Online quantitative survey of 91\u00a0endocrinologists.<\/p>\n","protected":false},"template":"","class_list":["post-409059","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/409059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/409059\/revisions"}],"predecessor-version":[{"id":409186,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/409059\/revisions\/409186"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=409059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}